Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levetiracetam + midazolam + phenytoin + valproic acid
- Development stage
- Unknown
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapeutic regimen consisting of levetiracetam, midazolam, phenytoin, and valproic acid, primarily utilized in the intensive care setting for the management of refractory status epilepticus (RSE). The regimen leverages multiple mechanisms of action to terminate persistent seizure activity: levetiracetam binds to synaptic vesicle protein 2A (SV2A) to modulate neurotransmitter release; midazolam acts as a positive allosteric modulator of GABA-A receptors to enhance inhibitory neurotransmission; phenytoin provides voltage-dependent blockade of sodium channels; and valproic acid increases GABA levels while also inhibiting sodium and calcium channels. Clinical data, particularly in pediatric populations, suggests this four-drug combination can be effective in cases where standard sequential therapy has failed.
- Other names
- phenytoin + levetiracetam + valproic acid + midazolam
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SV2A (Synaptic vesicle glycoprotein 2A)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)ABAT (4-aminobutyrate aminotransferase)
Beyond the preview
Go deeper on levetiracetam + midazolam + phenytoin + valproic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levetiracetam + midazolam + phenytoin + valproic acid.